MAPT and Alzheimer disease: The levels of neuropathological biomarkers of AD, including Aβ1–42, P-tau (T181), P-tau (S199), P-tau (T231), and P-tau (S396) and T-tau in CSF from AD-nHL and AD-HL groups were compared (Table 4).